Q-omics provides the consensus-scored KIAA1614 profile across patient tissues and cancer cell-line models. KIAA1614 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KIAA1614 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, KIAA1614 protein abundance shows 21,032 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, THCA, and HNSC as cancer lineages where KIAA1614 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIAA1614 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIAA1614 survival associations across molecular data types. KIAA1614 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIAA1614 RNA expression–survival associations across cancer types. High KIAA1614 expression shows unfavorable associations in ACC, KICH and LGG, but favorable associations in KIRC, KIRP and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KIAA1614 RNA expression.
This table summarizes KIAA1614 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KIAA1614. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIAA1614 shows lower tumor expression in THCA, KICH, BLCA and LUAD and higher tumor expression in HNSC and LIHC. The THCA box plot shows higher KIAA1614 RNA expression in normal versus tumor tissue (log2 FC = −1.607, t-test p < 0.001).
This table shows molecular features associated with KIAA1614 in patient tissues and cancer cell lines. In patient samples, KIAA1614 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, KIAA1614 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
